Bone Cancer - Pipeline Review, H1 2013

Description: Bone Cancer – Pipeline Review, H1 2013

Summary

Global Markets Direct's, 'Bone Cancer - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. Bone Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Bone Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Bone Cancer 11
Bone Cancer Therapeutics under Development by Companies 13
Bone Cancer Therapeutics under Investigation by Universities/Institutes 16
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Appendix 161
Methodology 161
Coverage 161
Secondary Research 161
Primary Research 161
Expert Panel Validation 161
Contact Us 162
Disclaimer 162

List of Tables
Number of Products Under Development for Bone Cancer, H1 2013 11
Products under Development for Bone Cancer – Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Celsion Corporation, H1 2013 25
Amgen Inc., H1 2013 26
Merck & Co., Inc., H1 2013 27
Exelixis, Inc., H1 2013 28
Bayer AG, H1 2013 29
Medivir AB, H1 2013 30
Osteologix, Inc., H1 2013 31
Green Cross Corporation, H1 2013 32
Merriion Pharmaceuticals Plc, H1 2013 33
Digna Biotech, S.L., H1 2013 34
Debiopharm Group, H1 2013 35
Amura Holdings Ltd., H1 2013 36
Alethia Biotherapeutics Inc., H1 2013 37
Hawthorn Pharmaceuticals, Inc., H1 2013 38
Deciphera Pharmaceuticals, LLC, H1 2013 39
Virobay Inc., H1 2013 40
Targa Therapeutics Corp., H1 2013 41
Assessment by Monotherapy Products, H1 2013 42
Assessment by Combination Products, H1 2013 43
Assessment by Stage and Route of Administration, H1 2013 45
Assessment by Stage and Molecule Type, H1 2013 47
Bone Cancer Therapeutics – Drug Profile Updates 106
Bone Cancer Therapeutics – Discontinued Products 151
Bone Cancer Therapeutics – Dormant Products 152
Bone Cancer Therapeutics – Dormant Products (Contd..1) 153
Bone Cancer Therapeutics – Dormant Products (Contd..2) 154

List of Figures
Number of Products under Development for Bone Cancer, H1 2013 11
Products under Development for Bone Cancer – Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 42
Assessment by Combination Products, H1 2013 43
Assessment by Route of Administration, H1 2013 44
Assessment by Stage and Route of Administration, H1 2013 45
Assessment by Molecule Type, H1 2013 46
Assessment by Stage and Molecule Type, H1 2013 47

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2517862/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Bone Cancer - Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2517862/
Office Code: SCD2LPS6

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________________________ Last Name: _______________________________________
Email Address: * _______________________________________
Job Title: ____________________________________________
Organisation: _________________________________________
Address: _____________________________________________
City: _________________________________________________
Postal / Zip Code: _____________________________________
Country: ______________________________________________
Phone Number: _________________________________________
Fax Number: __________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World